Autor según el artículo: Vilar-Ribó, L; Cabana-Domínguez, J; Martorell, L; Ramos-Quiroga, JA; Sanchez-Roige, S; Palmer, AA; Vilella, E; Ribasés, M; Muntané, G; Artigas, MS
Departamento: Medicina i Cirurgia
Autor/es de la URV: Martorell Bonet, Lourdes / Muntané Medina, Gerard / Vilella Cuadrada, Elisabet
Palabras clave: Deficit-hyperactivity disorder schizophrenia mortality mendelian randomization genome-wide association disease children childhood adults adhd
Resumen: There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes.
Áreas temáticas: Psychiatry and mental health Psychiatry Psicología Pharmacology & pharmacy Pharmacology Neurosciences Medicina ii Medicina i Interdisciplinar General medicine Farmacia Engenharias iv Educação física Ciências biológicas ii Ciências biológicas i
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
Direcció de correo del autor: gerard.muntane@urv.cat lourdes.martorell@urv.cat elisabet.vilella@urv.cat
Identificador del autor: 0000-0003-4999-2197 0000-0002-1887-5919
Fecha de alta del registro: 2024-08-03
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.nature.com/articles/s41386-023-01555-x
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Neuropsychopharmacology. 48 (7): 981-990
Referencia de l'ítem segons les normes APA: Vilar-Ribó, L; Cabana-Domínguez, J; Martorell, L; Ramos-Quiroga, JA; Sanchez-Roige, S; Palmer, AA; Vilella, E; Ribasés, M; Muntané, G; Artigas, MS (2023). Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan. Neuropsychopharmacology, 48(7), 981-990. DOI: 10.1038/s41386-023-01555-x
DOI del artículo: 10.1038/s41386-023-01555-x
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2023
Tipo de publicación: Journal Publications